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Summary 
We report the utilization of a very sensi- 
tive radioimmunoassay for plasma B-END, which 
has enabled us to examine the suppressibility of 
B-END-like material, under dexamethasone chal- 
lenge, on a population of depressed patient~. 
We have found that B-END-like material in plasma 
is suppressed by dexamethasone in a psychiatric 
control population, whereas suppression is less 
likely in endogenously depressed patients. 
There also appears to be a dissociation between 
cortisol and B-END measures (tested at 4:00 PM) 
in the endogenously depressed group. 
Several lines of evidence demonstrate an abnormality in the 
hypothalmic-pituitary-adrenal axis in patients with endogenous 
depression (1,2,3). There are multiple levels where the defect 
might be localized. The dexamethasone suppression test (DST) 
measures the pituitary-adrenal interface. This paper attempts 
to move the study of the endocrinology of depression to the 
level of the pituitary and brain. Thus, we are interested in 
measuring beta-endorphin since it is part of the same precursor 
molecule, pro-opiomelanocortin, as ACTH (4,5). We have used a 
dexamethasone challenge to begin to look at the regulation of 
the pituitary pro-opiomelanocortin system. Although one study 
reports no suppression with dexamethasone in normals, the plasma 
radioimmunoassay is difficult and may lead to false negatives 
(6). We have therefore addressed here the following two 
questions: a) Does dexamethasone suppress B-END in human 
plasma? and b) Is the pattern of B-END suppression altered in 
endogenous depression? 
Methods 
Blood collection was carried out via angiocatheter into 
chilled EDnA containing vacutainers. The samples were centri- 
fuged at 4vC for I0 minutes and were then aliquoted into plastic 
storage vials and acidified to a pH of 2.0 with 1 N HCI. The 
• • • O • • 
acldlfled serum was stored at -70 C untll extractlon. We used 
Sep Pak C~ cartridges (Waters) for ~ur extraction procedure 
which progided 90% recovery with H--B-END spiked human serum 
(9). 
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The radioimmunoassay was carried out in 150 mM Na phosphate 
buffer with 1% human serum albumin at pH 8.2 under disequili- 
brium incubation. The antiserum (rabbit Brenda) was used at a 
final concentration of 1:40,000 and separation was carried out 
by immunoprecipitation with goat antirabbit IgG. Cross- 
reactivity studies with our antibody showed 100% cross- 
reactivity with B-LPH and N-acetyl-B-END, 50% with B-END1_97, 
and 30% with N-acetyl-B-ENDq .., whereas there is no c~o~s- 
reactivity with alpha-EN~?Zlgamma-END, B-END?_~, B-ENDg_I7, 
methionine enkephalin, or alpha-melanocyte-stimu~a~ing hormone. 
The assay is capable of measuring <1.5 fmoles/assay tube (normal 
resting levels of B-END-like immunoreactivity are 2-5 
fmoles/ml). The validation of the assay and the chromatography 
of the material being measured have been described (9). 
Using this procedure we studied a mixed psychiatric control 
population (N=5) versus a group of endogenous depressives (N=6). 
Under dexamethasone challenge serum cortisol and serum B-END 
levels were measured. An 18 gauge angiocatheter was inserted 
into an antecubital arm vein at 1:30 PM; 20 ml blood samples 
were obtained at 20 minute intervals between 3:30 and 4:30 PM. 
All subjects were then given 1 mg of dexamethasone at 11:30 PM 
that evening and the catheter study was carried out in an 
identical fashion the following day. Both cortisol and B-END 
measures are reported as the means of the four time points 
between 3:30 and 4:30 PM. Thus: I) simultaneous cortisol and 
B-END measures were obtained; 2) subjects were their own 
controls; and 3) repeated measures enable us to control for 
stress and pulsatile release of B-END. The 4:00 PM time period 
was chosen since this is the time when the dexamethasone 
suppression test is most sensitive in separating endogenously 
depressed patients from normal individuals. 
Results 
Table 1 shows the results. The non-endogenous psychiatric 
control group showed a mean suppression of their B-END levels of 
45% + 8 as compared to 18% + 8 suppression for the endogenous 
depressives. The mean Hamilton rating for depression for the 
control group was 6 + 2 and 24 + 1 for the endogenous 
depressives. Further, t~ere is an absence of overlap between 
pre- and post-dexamethasone B-END levels in the controls, where- 
as there was considerable overlap in endogenous depressives. 
The post-dexamethasone B-END values were very closely clustered 
in the controls in contrast to much greater variability in the 
endogenous depressives. 
Since endogenously depressed patients usually exhibit 
cortisal values of greater than 5.0 ug/dl after dexamethasone, 
we have reviewed the B-END data for a similar cutoff. A 
conservative preliminary post-dexamethasone value of 2.5 fm/ml 
was above all non-endogenous post-dexamethasone values. 
As summarized by Table 2, B-END levels above 2.5 fm/ml 
identified five out of the six endogenous depressives, whereas 
post-dexamethasone cortisol levels identified only two of the 
six endogenous depressives. Note that there is good agreement 
for the absence of abnormal B-END and cortisol responses in the 
non-endogenous groups, whereas the agreement for abnormal 







X + S.E. 
Table 1 
Non-endogenous Psychiatric Controls 
Hamil ton 
BE Plasma level (fm/ml) Depression 
Pre dex Post dex Suppression Ratin@s 
6.8 + 0.8 1.8 + 0.3 70% i0 
3.7 T 0.4 1.8 T 0.3 51% 1 
2.6 + 0.2 2.0 + 0.2 23% 7 
2.8 • 1.2 1.5 ; 0.3 46% 8 
2.4 T 0.3 1.6 • 0.i 33% - 
3.5 + 0.7 .... 1.7 + 0.i 45% + 8 6 + 2 
Endogenous Depressives 
X BE Plasma level (fm/ml) 











3.6 + 0.4 5.2 + 0.8 0% 21 
3.3 • 0.8 3.2 T 1.7 4% 22 
10.2 • 1.6 5.8 • 1.8 43% 38 
1.8 • 0.3 1.2 • 0.2 32% 21 
5.4 • 0.9 3.8 • 0.5 31% 18 
3.9 • 1.2 4.0 • 0.9 0% 24 











#i (-) (-) 
#2 (-) (-) 
#3 (-) 0 (-) 0 
#4 (-) ~ (-) 
#5 (-) (-) 
#6 C+) (-) 
#7 (+) (-) 
#8 (+) 5 (-) 2 
#9 (-) 6 (+) 
#10 (+) (+) 
#ii (+) (-) 
responses is poor in the endogenously depressed group. It 
should be noted, however, that the combination of B-END and 
cortisol measures around the 4:00 PM time point identifies all 
of the endogenously depressed patients. 
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Discussion 
These results suggest that B-END-like material in plasma is 
suppressed by dexamethasone in a non-endogenous psychiatric 
population, whereas suppression is less likely in endogenously 
depressed patients. Of interest is the observation that the 
combination of both cortisol and B-END-like measures identifies 
all of the endogenously depressed patients. The dissociation 
between cortisol and B-END-like values in the endogenously 
depressed patients warrants further investigation in view of 
reports suggesting that B-END and ACTH are secreted in equimolar 
amounts (7). Simultaneous measures of ACTH, B-END, and cortisol 
may help explain this lack of agreement and possibly help 
localize the defect. This discrepancy may also be related to 
the 3:30 to 4:30 PM sampling time since B-END and cortisol are 
regulated differently and have different half lives (8). There 
may be a time period at which cortisol and B-END measures are 
more tightly linked. Thus, the best time point post-dexametha- 
sone B-END measurement needs to be determined. Twenty-four hour 
circadian rhythm studies are thus imperative. The large 
differences in the Hamilton ratings in the psychiatric controls 
versus the endogenous depressives suggests that severity of 
illnes may account for the lack of suppression in the endogenous 
depressives; thus, future studies need to control for this 
variable. Studies on normal controls and sex differences are 
now being carried out. 
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